InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced that its next-generation TRK inhibitor, zurletrectinib (ICP-72...
Eurofins Consumer Product Testing Vietnam has completed a major expansion, seeing the laboratory move to a purpose-built 7,000 sq. m laboratory in Ho Chi...
Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Co...
Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlyt...
Angel Yeast (SH600298), a global leader in yeast and fermentation solutions, has begun trial production at its new specialty yeast project in the Baiyang...
InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced tha...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachuse...
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in Europe Omlyclo™ 300 mg/2ml prefilled syringe (PFS) p...
Covers exclusive rights to S-pindolol, the novel therapy in development for the treatment of cachexia, in India and South Asia Represents a major step...
Nxera Pharma Co., Ltd. announced a focused restructuring designed to concentrate investment and resources on efficient platforms, programs and products w...
Teijin Limited and BioVaram, the brand name of the UR Advanced Therapeutics Pvt Ltd. (URAT), announced that they have signed a business alliance agreement ...
Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $10...
The €190 million acquisition of VISUfarma marks a pivotal moment in Lupin’s transformation into a global specialty-led biopharma. With VISUfarma...
Industry report measures progress in six main areas: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, government polic...
© 2026 Biopharma Boardroom. All Rights Reserved.
